The complaint

The case is Nutramax Laboratories, Inc. v. Neviss LLC, No. 2:26-cv-12437 (C.D. Cal.), filed October 23, 2026. The plaintiffs are Nutramax Laboratories, Inc. and its wholly owned subsidiary Nutramax Laboratories Consumer Care, Inc., both South Carolina corporations based in Lancaster, South Carolina. The complaint says Nutramax Consumer Care distributes Avmacol in the United States as exclusive licensee of both patents in the field of human health supplements. Neviss LLC is a California limited liability company based in Ontario, California, and venue is pleaded under 28 U.S.C. 1400(b) on the ground that Neviss resides in the district. The complaint is signed by Erik J. Carlson of Alston & Bird LLP and also lists Natalie C. Clayton of the same firm, pro hac vice forthcoming.

The patents

Both patents are titled "Compositions Comprising Sulforaphane or a Sulforaphane Precursor and a Mushroom Extract or Powder" and name Brian Cornblatt, Grace Cornblatt, Anton Bzhelyansky, and Robert Henderson as inventors. The '178 patent issued March 10, 2020, and the '186 patent issued May 23, 2023. The complaint alleges Nutramax Laboratories, Inc. owns both by assignment.

Claim 1 of the '178 patent covers an orally administrable composition with a synergistic combination of a sulforaphane precursor, a glucosidase enzyme capable of converting the precursor to sulforaphane, a glucosidase enzyme cofactor, and a glucan. Claim 1 of the '186 patent covers the same combination with a precursor-to-glucan ratio from about 50:1 to about 1:50. In both patents, claim 5 adds a yeast extract or powder comprising the glucan, and claim 6 specifies a beta-glucan. The complaint asserts at least claims 1, 5, 6, 14, 17, 18, 22, and 25 of the '178 patent and at least claims 1, 5, 6, 11, 15, 16, 19, 20, 25, and 29 of the '186 patent.

The accused product

The complaint accuses the Neviss Kids 4+ & Adults Liposomal Sulforaphane from Broccoli Sprout Extract Superfood Gummies sold on Amazon. It alleges the gummies combine broccoli sprout extract with glucoraphanin, a myrosinase enzyme, vitamin C, beta glucan from yeast extract, and liposomal sulforaphane, at about 1.3 parts sulforaphane precursor to 1 part glucan per serving. It alleges, on information and belief, that the combination is synergistically effective, citing Neviss's own marketing of a "dual-activation system."

Nutramax alleges that it sent Neviss letters on August 17 and September 17, 2026, the second with claim charts, and that Neviss did not respond. It alleges that Neviss then changed the ingredient image and description in the Amazon listings named in the letters, removing references to myrosinase and dual activation, while a unit ordered through an altered listing and delivered October 3, 2026 still listed a "Dual Activator Sulforaphane Blend." Count I ('178 patent) and Count II ('186 patent) each allege direct infringement under 35 U.S.C. 271(a) and induced and contributory infringement under 35 U.S.C. 271(b) and (c), and the complaint alleges willful infringement.

The relief sought

Nutramax asks for a judgment of infringement, damages including supplemental post-verdict damages with interest and costs, a judgment of willful infringement, a permanent injunction, enhanced damages under 35 U.S.C. 284, an exceptional-case finding, and attorneys' fees under 35 U.S.C. 285. It demands a jury trial.

What to watch next

Watch for service on Neviss and its answer or Rule 12 motion.